Log in

NASDAQ:PRQRProQR Therapeutics Competitors & Alternatives

$4.99
+0.01 (+0.20 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.91
Now: $4.99
$5.21
50-Day Range
$4.98
MA: $5.68
$6.46
52-Week Range
$4.46
Now: $4.99
$10.98
Volume129,500 shs
Average Volume123,622 shs
Market Capitalization$248.25 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52

Competitors

ProQR Therapeutics (NASDAQ:PRQR) Vs. NBRV, AMPH, ARCT, RYTM, VBIV, and GOSS

Should you be buying PRQR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ProQR Therapeutics, including Nabriva Therapeutics (NBRV), Amphastar Pharmaceuticals (AMPH), Arcturus Therapeutics (ARCT), Rhythm Pharmaceuticals (RYTM), VBI Vaccines (VBIV), and Gossamer Bio (GOSS).

ProQR Therapeutics (NASDAQ:PRQR) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares ProQR Therapeutics and Nabriva Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22
Nabriva Therapeutics$9.48 million103.90$-82,760,000.00($1.12)-0.62

ProQR Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ProQR Therapeutics and Nabriva Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00403.00
Nabriva Therapeutics04202.33

ProQR Therapeutics presently has a consensus target price of $30.6667, indicating a potential upside of 514.56%. Nabriva Therapeutics has a consensus target price of $3.75, indicating a potential upside of 444.27%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe ProQR Therapeutics is more favorable than Nabriva Therapeutics.

Volatility & Risk

ProQR Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.

Insider & Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ProQR Therapeutics and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-76.30%-59.26%
Nabriva Therapeutics-1,001.59%-231.00%-107.55%

Summary

ProQR Therapeutics beats Nabriva Therapeutics on 8 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Amphastar Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22
Amphastar Pharmaceuticals$322.36 million2.92$48.94 million$0.3656.50

Amphastar Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Amphastar Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00403.00
Amphastar Pharmaceuticals03002.00

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Amphastar Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 8.16%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Amphastar Pharmaceuticals.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Amphastar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-76.30%-59.26%
Amphastar Pharmaceuticals15.90%4.99%3.65%

Summary

Amphastar Pharmaceuticals beats ProQR Therapeutics on 9 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Arcturus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22
Arcturus Therapeutics$20.79 million44.86$-25,990,000.00($2.15)-21.81

Arcturus Therapeutics has higher revenue and earnings than ProQR Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00403.00
Arcturus Therapeutics01602.86

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Arcturus Therapeutics has a consensus price target of $37.1429, suggesting a potential downside of 20.79%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Arcturus Therapeutics.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 23.8% of Arcturus Therapeutics shares are owned by institutional investors. 19.2% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-76.30%-59.26%
Arcturus Therapeutics-151.34%-409.05%-58.51%

Summary

ProQR Therapeutics beats Arcturus Therapeutics on 7 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Rhythm Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.44

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00403.00
Rhythm Pharmaceuticals10502.67

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Rhythm Pharmaceuticals has a consensus price target of $34.1667, suggesting a potential upside of 62.62%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Rhythm Pharmaceuticals.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 92.0% of Rhythm Pharmaceuticals shares are owned by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-76.30%-59.26%
Rhythm PharmaceuticalsN/A-67.50%-60.13%

Summary

ProQR Therapeutics beats Rhythm Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and VBI Vaccines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00403.00
VBI Vaccines00403.00

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. VBI Vaccines has a consensus price target of $4.75, suggesting a potential upside of 21.17%. Given ProQR Therapeutics' higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than VBI Vaccines.

Valuation & Earnings

This table compares ProQR Therapeutics and VBI Vaccines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22
VBI Vaccines$2.22 million407.27$-54,810,000.00($0.46)-8.52

VBI Vaccines has higher revenue and earnings than ProQR Therapeutics. VBI Vaccines is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProQR Therapeutics and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-76.30%-59.26%
VBI Vaccines-2,133.79%-57.79%-40.81%

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of VBI Vaccines shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

VBI Vaccines beats ProQR Therapeutics on 7 of the 11 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Gossamer Bio and ProQR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00803.00
ProQR Therapeutics00403.00

Gossamer Bio presently has a consensus price target of $29.50, suggesting a potential upside of 125.36%. ProQR Therapeutics has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Gossamer Bio.

Valuation and Earnings

This table compares Gossamer Bio and ProQR Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-3.98
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.22

Gossamer Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gossamer Bio and ProQR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-53.83%-45.47%
ProQR TherapeuticsN/A-76.30%-59.26%

Volatility & Risk

Gossamer Bio has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Institutional and Insider Ownership

58.1% of Gossamer Bio shares are owned by institutional investors. Comparatively, 59.0% of ProQR Therapeutics shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$0.69+0.0%$984.27 million$9.48 million-0.64
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.4$20.34+2.4%$939.67 million$322.36 million19.37
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.5$46.89+3.7%$932.75 million$20.79 million-22.76Analyst Report
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.5$21.01+4.2%$926.37 millionN/A-5.47
VBI Vaccines logo
VBIV
VBI Vaccines
1.8$3.92+3.8%$904.14 million$2.22 million-11.20Analyst Downgrade
GOSS
Gossamer Bio
2.1$13.09+0.0%$868.63 millionN/A-3.97
Retrophin logo
RTRX
Retrophin
1.3$20.04+0.5%$864.84 million$175.34 million-8.18
PHAT
Phathom Pharmaceuticals
1.7$29.24+2.7%$846.92 millionN/A-2.09
Cara Therapeutics logo
CARA
Cara Therapeutics
1.7$17.63+0.1%$825.01 million$19.89 million-6.91
Kura Oncology logo
KURA
Kura Oncology
1.6$17.87+0.1%$811.95 millionN/A-11.53
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.66+5.9%$798.31 million$35.22 million-4.71Analyst Report
Endo International logo
ENDP
Endo International
1.5$3.44+2.3%$790.18 million$2.91 billion-2.82
MORF
Morphic
1.4$25.67+0.5%$786.71 million$16.98 million-4.11
STOK
Stoke Therapeutics
1.5$23.40+1.1%$771.57 millionN/A-13.00
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.4$20.39+4.7%$769.27 millionN/A-5.93
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.32+11.3%$753.43 million$82.27 million-7.45
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$23.02+2.4%$753.27 million$15.96 million-6.71
Omeros logo
OMER
Omeros
1.5$13.61+1.5%$741.89 million$111.81 million-7.87
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.37+3.6%$722.14 million$150,000.00-4.81Analyst Report
FREQ
Frequency Therapeutics
1.3$22.98+0.1%$712.68 million$28.95 million-10.03Insider Selling
APLT
Applied Therapeutics
1.4$30.47+2.5%$674.20 millionN/A-8.99
Kadmon logo
KDMN
Kadmon
1.5$4.21+1.9%$673.71 million$5.09 million-6.01
Homology Medicines logo
FIXX
Homology Medicines
1.5$14.85+4.6%$671.42 million$1.67 million-5.69
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$48.45+2.5%$663.04 million$195.89 million285.02
PRVB
Provention Bio
1.8$13.17+5.5%$638.35 millionN/A-12.66
CUE
Cue Biopharma
1.6$22.35+1.4%$635.85 million$3.46 million-13.80
KROS
Passage Bio
1.3$32.75+2.1%$628.44 millionN/A0.00
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.49+0.9%$626.78 million$227.19 million5.37
Stemline Therapeutics logo
STML
Stemline Therapeutics
1.4$11.83+0.0%$621.21 million$43.22 million-7.44Heavy News Reporting
RAPT
RAPT Therapeutics
1.5$25.46+4.0%$620.55 millionN/A-2.57
APRE
Aprea Therapeutics
1.3$29.42+4.8%$619.43 millionN/A-6.30
Radius Health logo
RDUS
Radius Health
2.1$13.33+0.5%$618.36 million$173.32 million-4.81
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.6$7.26+0.4%$605.74 million$120,000.00-3.61
Molecular Templates logo
MTEM
Molecular Templates
1.6$12.93+0.9%$591.29 million$22.27 million-5.96
BCEL
Atreca
1.8$20.66+2.3%$581.27 millionN/A-3.63Analyst Downgrade
AnaptysBio logo
ANAB
AnaptysBio
1.2$21.24+6.1%$579.37 million$8 million-6.87
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.7$16.73+2.5%$574.44 million$296.70 million-44.03
Ardelyx logo
ARDX
Ardelyx
1.6$6.42+2.8%$570.92 million$5.28 million-4.90
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.8$7.68+0.3%$556.73 million$36.14 million-6.80Unusual Options Activity
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.5$10.16+3.2%$554.46 million$6.07 million-3.98Heavy News Reporting
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$15.35+0.4%$554.06 million$1.52 million-8.16
Athersys logo
ATHX
Athersys
2.0$2.81+3.2%$552.09 million$5.63 million-9.37
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.2$11.49+3.8%$525.02 million$1.98 million-6.42
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
2.0$4.94+1.4%$510.87 million$102.31 million12.35
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.62+1.2%$509.08 million$143.01 million-0.92
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.4$15.29+1.9%$502.21 million$1.19 million-6.32
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.8$6.81+1.0%$494.38 millionN/A-16.21
NXTC
NextCure
1.6$17.88+1.7%$492.01 million$6.35 million-18.06
Urogen Pharma logo
URGN
Urogen Pharma
1.6$23.35+1.3%$487.94 million$20,000.00-4.03Analyst Upgrade
MIRM
Mirum Pharmaceuticals
1.6$19.03+3.4%$483.17 millionN/A-2.44
This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.